# Enteric Infections, Dysbiosis, and Metabolic Dysfunction: The Role of Diarrheagenic Pathogens in Insulin Resistance

## TL;DR

This paper explores how gut infections and microbial changes contribute to insulin resistance and diabetes, highlighting new therapeutic possibilities.

## Contribution

The paper introduces a novel perspective on how diarrheagenic pathogens influence insulin resistance through gut microbiota and immune interactions.

## Key findings

- Diarrheagenic pathogens disrupt gut microbiota and increase intestinal permeability.
- Pathogens contribute to metabolic endotoxemia and chronic inflammation linked to insulin resistance.
- Modulating gut microbiota or reducing pathogen-driven inflammation may improve metabolic outcomes.

## Abstract

Type 2 diabetes and insulin resistance are increasingly recognized as conditions influenced not only by genetic and lifestyle factors but also by infectious and microbial exposures. Diarrheagenic pathogens, including enterotoxigenic, enteroaggregative, and enterohemorrhagic Escherichia coli, as well as other enteric microorganisms, disrupt the gut microbiota and compromise intestinal barrier integrity. These alterations promote dysbiosis, increased intestinal permeability, and systemic exposure to lipopolysaccharides and other microbial products, leading to metabolic endotoxemia and chronic low-grade inflammation. In parallel, pathogen-induced modulation of host immune responses contributes to adipose tissue inflammation, mitochondrial dysfunction, and impaired insulin signaling. This review summarizes current evidence linking diarrheagenic pathogens to insulin resistance, with emphasis on the microbiota–immune–metabolism axis. Understanding these interactions highlights novel perspectives on the pathogenesis of insulin resistance and suggests that targeted modulation of the gut microbiota or reduction in pathogen-driven inflammation may represent therapeutic opportunities to improve metabolic outcomes.